Ron Leuty

Ron Leuty

#Biotech reporter @SFBusinessTimes; struggling runner; hardcore Detroit Tigers fan. Natl coverage @biotechday 415-288-4939 (desk)

10730 followers  •  1305 follow  •    •

Invesco snags six shell buildings in Alameda geared toward biotech

A pill to make your cells younger? This company wants you to swallow the fountain of youth via @SFBusinessTimes 

Two of the nation’s biggest steelmakers are keeping older mills closed because of the high cost of restarting them and the threats to their survival from rivals’ new plants via @WSJ 

$ELAN finds juicy bones in deal for doggy drug developer $KIN

Seattle hasn't lost its appeal with biotech execs — sorry Bothell via @PSBJ 

Athira CEO placed on temporary leave pending review of WSU research via @PSBJ 

The Petri Dish: New diversity numbers, Exelixis CMO takes leave, migraine nasal powder moves forward via @SFBusinessTimes 


Coming March 12: #WomenWhoLeadInLifeSciences  event, featuring the three women leaders of startup Lycia Therapeutics - including serial founder @CarolynBertozzi  of @Stanford  - and a great panel from @FivePrime_FPRX  @genentech  @AllogeneTx  and @CaribouBio 

After Chapter 11, Martin Shkreli and a name change, Peninsula biotech now looks to tackle Covid's 'cytokine storm' with emergency use OK $HGEN #Covid  #EUA  via @SFBusinessTimes 

Experimental drug for ALS, dreamed up in a dorm room, offers patients glimmer of hope via @statnews 

How @HelloDotLab  hopes to change women's health with a simple blood test #endometriosis  #womenshealth 

People ask me about my beats — biotech and sports — assuming they never collide. Yeah, never … Steph Curry goes 1-on-1 with Tony Fauci on COVID-19 via @SFBusinessTimes 

'It's complicated': How a @UCSF  professor is turning George Floyd's death into an outlet for Black voices in health care via @SFBusinessTimes  @ash_mcmully  @thenocturnists 

How $TMO and @UCSF  are going small to go big to take cell therapies from bench to bedside for patients, researchers and Bay Area biopharma companies via @SFBusinessTimes 

With $30M and Stanford immunotherapy pioneer, biotech eyes one of the toughest brain diseases via @SFBusinessTimes